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Abstract
The classification of most chronic pain disorders gives emphasis to anatomical location of the pain 
to distinguish one disorder from the other (eg, back pain vs temporomandibular disorder [TMD]) 
or to define subtypes (eg, TMD myalgia vs arthralgia). However, anatomical criteria overlook 
etiology, potentially hampering treatment decisions. This study identified clusters of individuals 
using a comprehensive array of biopsychosocial measures. Data were collected from a case–
control study of 1031 chronic TMD cases and 3247 TMD-free controls. Three subgroups were 
identified using supervised cluster analysis (referred to as the adaptive, pain-sensitive, and global 
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symptoms clusters). Compared with the adaptive cluster, participants in the pain-sensitive cluster 
showed heightened sensitivity to experimental pain, and participants in the global symptoms 
cluster showed both greater pain sensitivity and greater psychological distress. Cluster 
membership was strongly associated with chronic TMD: 91.5% of TMD cases belonged to the 
pain-sensitive and global symptoms clusters, whereas 41.2% of controls belonged to the adaptive 
cluster. Temporomandibular disorder cases in the pain-sensitive and global symptoms clusters also 
showed greater pain intensity, jaw functional limitation, and more comorbid pain conditions. 
Similar results were obtained when the same methodology was applied to a smaller case–control 
study consisting of 199 chronic TMD cases and 201 TMD-free controls. During a median 3-year 
follow-up period of TMD-free individuals, participants in the global symptoms cluster had greater 
risk of developing first-onset TMD (hazard ratio = 2.8) compared with participants in the other 2 
clusters. Cross-cohort predictive modeling was used to demonstrate the reliability of the clusters.
Keywords
Temporomandibular disorders; Clustering; Classification of chronic pain
 1. Introduction
Chronic pain conditions affect 100 million Americans and incur annual health care costs of 
$635 billion.32 They are difficult to manage in part because they are commonly defined as 
anatomically based disorders (eg, temporomandibular disorder [TMD], back pain, etc) 
without adequate recognition of mediating nonanatomical etiological processes.13,18 For 
example, low-back pain is distinguished from TMD because symptoms are felt in different 
parts of the body, yet both types of pain share many common characteristics.13,74 The 
predominantly anatomical focus of pain classification is in contrast to other types of diseases 
that additionally consider etiology in their classification. For example, myocardial infarction 
and stroke are anatomically distinct diseases, yet both have subtypes etiologically classified 
as atherosclerosis. If anatomically classified pain disorders were additionally classified using 
etiological criteria, pain management could be tailored to address underlying etiological 
mechanisms.
Temporomandibular disorders are a case in point. Temporomandibular disorder diagnosis is 
based on painful symptoms in the orofacial region.59 Rigorous classification methods use 
these criteria, allowing users to provide valid anatomic-based diagnoses. However, risk 
factors are not currently part of the diagnosis. Researchers, in contrast, have identified 
TMD-related risk factors that point to different etiological mechanisms such as 
psychological distress and neurosensory regulatory processes, although these mechanisms 
have not yet been used to subclassify TMD.
The objective of this study was to identify clinically relevant groups of individuals 
(hereafter, “clusters”) who have similar profiles of risk factors for chronic pain that can be 
reliably distinguished statistically. Specifically, we focus on risk factors signifying 
biopsychosocial processes that influence chronic pain, such as pain sensitivity and 
psychological distress. Because there are multiple such risk factors, it is useful to envisage 
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sets of individual risk factors that, in combination, represent sufficient component causes.56 
This study focused primarily on chronic TMD, although TMD shares risk factors with other 
chronic pain conditions,13,74 so clusters associated with the frequency and severity of TMD 
are likely to also be associated with other painful conditions. Among people with TMD, we 
expect some clusters to be associated with more severe TMD symptoms. We further 
hypothesize that some individuals who are currently TMD pain free will nevertheless have 
characteristics similar to those with chronic TMD. That is, if this hypothesis is correct, we 
would expect to observe currently TMD pain–free individuals who cluster together with 
chronic TMD cases and exhibit higher risk of developing first-onset TMD. This is a step 
toward the ultimate goal of a classification system for chronic pain that includes etiology62 
and builds on existing anatomically based classification systems such as Axis I of the 
Diagnostic Criteria for Temporomandibular Disorders59 and multidimensional systems such 
as the ACTTION-American Pain Society Pain Taxonomy.18
One challenge is that traditional clustering methods have poor reproducibility. To address 
this problem, we used the gap statistic70 to determine the optimal number of clusters and 
used split-half methodology to verify cluster assignment reliability. Finally, we sought 
evidence of etiological validity by examining the extent to which cluster classification 
predicted incidence of first-onset TMD.
 2. Methods
Data were analyzed from 2 observational studies. After summarizing each study and the data 
collected, the sections that follow describe 4 steps used in data analysis, namely: (1) variable 
selection for supervised cluster analysis; (2) cluster discovery; (3) evaluation of cluster 
reliability; and (4) cluster validation.
 2.1. Description of the OPPERA study
The Orofacial Pain: Prospective Evaluation and Risk Assessment (OPPERA) study is a 
prospective cohort study described previously. 61 The study recruited participants with and 
without chronic TMD (cases and controls, respectively) through advertisements, emails, 
flyers, and word of mouth. Participants were community-based volunteers, recruited from 
areas surrounding academic health centers at 4 U.S. study sites: Baltimore, MD; Buffalo, 
NY; Chapel Hill, NC; and Gainesville, FL. Participants were recruited from May 2006 to 
May 2013. Chronic TMD was classified based on the Research Diagnostic Criteria for 
Temporomandibular Disorder (RDC/TMD).15 In summary, the 2 criteria for TMD cases 
were (1) history of ≥5 days of facial pain in the preceding 30 days and (2) during 
examination, evoked pain in response to jaw movement or examiner palpation of masticatory 
muscles and/or temporomandibular joints.
Participants enrolled as controls were followed for up to 5 years to identify incident cases of 
first-onset TMD. After enrollment, they completed a questionnaire every 3 months to screen 
for TMD symptoms. Those reporting symptoms were examined by clinicians to determine 
whether the participant had developed first-onset TMD using the same 2 criteria. See Ref. 1 
for a more detailed description of the OPPERA follow-up protocol to evaluate first-onset 
TMD.
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 2.2. Description of the UNC study
The second study (hereafter referred to as “the UNC cohort”) used a case–control design, 
recruiting non-Hispanic white female participants between 2005 and 2009 from individuals 
reporting for treatment at the Orofacial Pain Clinic at the University of North Carolina in 
Chapel Hill (UNC) and from communities around Chapel Hill, NC using advertisements, 
flyers, and mass email. Temporomandibular disorder was classified using the same 
RDC/TMD criteria described for the OPPERA study.15 See Refs. 7 and 8 for a more detailed 
description of the UNC cohort, including the full inclusion and exclusion criteria.
The study protocol for both studies was approved by the institutional review boards at all 
participating institutions. All participants in both studies provided written informed consent 
for all study procedures.
 2.3. Study instruments and measures
At enrollment, participants in each study completed a similar battery of questionnaires, 
measurements, and clinical assessments as summarized below and in detail 
elsewhere.1,20,26,41,48,61,64 Unless otherwise noted, the same measures were collected using 
the same methods in each study.
 2.3.1. Sociodemographic characteristics—The study participants’ age, sex, race, 
and ethnicity were recorded.
 2.3.2. Clinical characteristics—Participants completed the Comprehensive Pain and 
Symptom Questionnaire,48 which evaluated the frequency and intensity of headaches, the 
presence of 6 nonspecific orofacial symptoms (eg, stiffness, cramping, etc), and the presence 
of 20 conditions known to be comorbid with TMD (eg, fibromyalgia, depression, etc). The 
Graded Chronic Pain Scale75 evaluated pain intensity and pain interference separately for 
orofacial pain and chronic pain outside the orofacial region.
For participants with TMD pain, the Screening Pain Self Report questionnaire evaluated the 
participant’s current level of orofacial pain and percentage of the waking day with pain. Pain 
unpleasantness and intensity were also evaluated using the Gracely Box Scale.24
Participants completed the 12-item Short Form Health Survey (SF-12) questionnaire 
yielding a Physical Functioning Scale and a Mental Health Scale. Participants in OPPERA 
study also completed the Jaw Functional Limitation Scale,43,47 a 20-item instrument that 
measures limitation in the use of the jaw, and the Oral Behaviors Checklist,49,50 which is a 
21-item instrument that evaluates the frequency of a series of parafunctional oral behaviors.
 2.3.3. Autonomic function—Blood pressure readings were taken from a cuff placed 
on the upper left arm. In the OPPERA cohort, heart rate variability (HRV) was measured 
with electrical leads placed at the left second rib (ground), right second rib, and lower left 
torso. Electrocardiogram signals were examined for impedance (defined as below 300 kΩ), 
digitized (1024 samples per second), filtered for artifacts, displayed in real time, and stored 
for offline analysis. Autonomic profiles consisting of resting blood pressure, heart rate, and 
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base 10 logarithmic HRV measures of total power, high-frequency values, and low-
frequency values were computed based on a 20-minute rest period as described previously.41
 2.3.4. Psychophysical measures of responsiveness to experimentally 
evoked pain—For the OPPERA cohort, pressure pain thresholds (PPTs) were measured 
using a hand-held algometer with 1 cm2 flat tip and a digital display (Somedic, Hörby, 
Sweden). Measurements were obtained from 5 sites on the face, shoulder, and arm. For the 
UNC cohort, PPTs were measured using a 1 cm2 flat-tipped algometer (Pain Diagnostics 
and Treatment, GreatNeck, NY) that was applied to the same locations that were used in the 
OPPERA study.
Heat pain thresholds and tolerance were determined using a computer-controlled thermode 
(2.56 cm2 ATS Pathway thermode, Medoc Inc). The threshold was measured using an 
ascending method of limits. The baseline temperature of the probe was 32°C, which was 
increased at a rate of 0.5°C/s. After threshold and tolerance measures, brief, repetitive 
suprathreshold thermal stimuli were applied to measure suprathreshold pain intensity and the 
temporal summation of heat pain (5.73 cm2 CHEPS Pathway thermode, Medoc Inc). This 
was performed in 3 iterations in the OPPERA study, with target temperatures of 46°C, 48°C, 
and 50°C, where the temperature was delivered at a rate of 20°C/s for approximately 1 
second to produce a hold time of 750 milliseconds at the desired target temperature. The 
interpulse interval was between 2.4 and 2.5 seconds to yield a peak-to-peak interpulse 
interval of 3. The procedure was performed at only 2 temperatures (namely, 47°C and 50°C) 
in the UNC cohort (2.56 cm2 ATS thermode, Medoc Inc), where the target temperature was 
delivered at 9°C/s for 1 second with a 2-second interpulse interval, which also resulted in a 
peak-to-peak interpulse interval of 3 seconds. The perceived intensity of each thermal pulse 
was reported by the participants on a 0-to-100 numeric scale, as previously described.40 
Several measures derived from the heat pain temporal summation protocol were considered, 
including the first pulse rating for series of thermal pulses, a measure of the area under the 
temporal summation curve derived by summing the numerical ratings for each pulse in a 
train of thermal stimuli delivered at the specified target temperature (ie, 46°C, 48°C, and 
50°C), and “delta” (defined as the difference between the maximum pain rating and the first 
pulse rating). After sensation pain ratings were collected at 15 and 30 seconds after the 
delivery of the final pulse for each thermal train.
In the OPPERA cohort, pricking pain sensitivity was assessed using a set of weighted probes 
and protocols similar to those used by the German Neuropathic Pain Network.54 Stimuli 
were applied to the dorsum of digits 2 to 4. Measures included pain threshold, ratings of 
pain intensity in response to the 256-mN and 512-mN probes, and temporal summation of 
pain using the same 2 probes. After sensations were also collected at 15 and 30 seconds after 
the last stimulus in each train of stimuli.
 2.3.5. Psychosocial questionnaires—The Coping Strategies Questionnaire–Revised 
evaluates how individuals cope with pain on cognitive and behavioral scales.55 Coping 
Strategies Questionnaire–Revised responses have previously been related to experimental 
pain responses.22 The Eysenck Personality Questionnaire assesses the major personality 
dimensions of extroversion, neuroticism, and psychoticism. 17 Extroversion and neuroticism 
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have been associated with affective distress and illness behavior in patients with chronic 
pain.27 The Kohn Reactivity Scale measures an individual’s level of reactivity or nervous 
system arousability, which has been shown to have a negative correlation with pain tolerance 
and perception.14 The Life Experiences Survey provides a measure of stressful life changes 
and their associated impact.58 The Lifetime Stressor List/Post-Traumatic Stress Disorder 
(PTSD) Checklist-Civilian Version (LSL) asks participants to indicate whether they have 
experienced a traumatic event and to evaluate the degree to which they experienced PTSD 
symptoms related to the event.77 The Pain Catastrophizing Scale assesses pain 
catastrophizing in an individual67 and is associated with higher levels of pain and physical 
disability.51 The Pennebaker Inventory for Limbic Languidness measures the frequency with 
which a person experiences common physical symptoms and sensations.52 Patients with 
chronic pain have higher scores on the Pennebaker Inventory for Limbic Languidness than 
pain-free controls.44 The Profile of Mood States provides an assessment of both positive and 
negative mood dimensions. Subjects respond to various mood-related items by indicating the 
extent to which they describe their current mood.38 The Pittsburgh Sleep Quality Index 
evaluates the quality of the respondent’s sleep in the previous month.6 The Perceived Stress 
Scale measures the degree to which respondents appraise situations that occurred during the 
last month as stressful.9 The Symptom Checklist-90-Revised (SCL-90R) assesses an 
individual’s psychological distress in 9 symptom areas, including anxiety, depression, and 
somatization.12 The State-Trait Anxiety Inventory assesses anxiety through 2 questionnaires. 
One assesses state anxiety, or current, event-related anxiety, whereas the other assesses trait 
anxiety, or general, personality-based anxiety.65
Participants in OPPERA completed all of the above questionnaires. Participants in the UNC 
study did not complete the Eysenck Personality Questionnaire, Life Experiences Survey, 
LSL, or Pittsburgh Sleep Quality Index but completed the others.
 2.3.6. Environmental risk factors—Three putative environmental risk factors were 
considered for both studies: self-reported lifetime history of jaw injury, self-reported lifetime 
history of smoking, and history of at least one traumatic life event on the LSL. Each of these 
environmental risk factors has been previously shown to be strongly associated with chronic 
TMD.20,48 Two additional putative risk factors were considered for the OPPERA study, 
namely, self-reported lifetime history of oral contraceptive use and current oral contraceptive 
use. (Males were excluded for the analysis on oral contraceptive use.) Some previous studies 
have found an association between hormonal contraceptive use and TMD.36
 2.4. Clustering methodology
 2.4.1. Variable selection for supervised cluster analysis—Clusters were 
identified using a supervised clustering method that was originally proposed by Bair and 
Tibshirani.2 Supervised clustering is useful in situations when one wishes to identify clusters 
associated with an outcome of interest based on a large number of variables, some of which 
are weakly (or not at all) associated with the outcome. The first step in this procedure selects 
variables that are most strongly associated with TMD from among the measures of pain 
sensitivity and psychological distress. This step of variable selection is one of the novel 
aspects of supervised cluster analysis, a method designed to overcome shortcomings of 
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conventional k-means clustering. The conventional approach can be problematic, 
particularly for high-dimensional data sets, when clusters may differ from one another with 
respect to only a subset of the variables. If one attempts to identify clusters using all the 
variables in such a data set, the quality of the resulting clusters is likely to be poor because 
the irrelevant variables will add “noise” to the clusters.2,65
Another shortcoming of conventional clustering methods is that they are unsupervised, 
meaning that they do not consider outcome variables. In many situations, one wishes to 
identify clusters that are associated with an outcome of interest. For example, in this study, 
we wish to identify clusters that are associated with the presence and severity of TMD. In 
many data sets, there are multiple possible clusters, and not all clusters will be associated 
with the outcome of interest. Conventional clustering methods may identify clusters that are 
unrelated to the outcome of interest. In contrast, supervised clustering has been shown to 
identify clusters associated with an outcome of interest when conventional clustering fails to 
identify such clusters.2
In the first step, we therefore selected the variables most strongly associated with the 
outcome of interest. The number of variables selected may affect the results, so it is 
necessary to choose the number of variables to use to form the clusters. We denote the 
number of variables used to form the clusters by M, so we select the M variables most 
strongly associated with chronic TMD. We considered 4 different values of M: 15, 20, 25, 
and 30. The strength of the association between each variable and chronic TMD in the 
OPPERA cohort was evaluated by performing logistic regression to predict TMD case status 
based on the variable of interest plus dummy variables for the 4 OPPERA study sites. 
Because there was only one study site for the UNC cohort (and hence no need to use logistic 
regression to control for this possible confounder), the strength of the association between 
each variable and chronic TMD was evaluated by performing t-tests to test the null 
hypothesis that the mean value of each variable did not differ between cases and controls.
Pain sensitivity and psychological distress were the domains of interest based on our 
previously described model; wherein, these types of measures represent the primary 
etiological risk factors for TMD and other chronic pain conditions.11,33 Other variables 
collected in the 2 studies (such as clinical variables) were excluded because of concern that 
they may represent consequences of TMD rather than possible underlying mechanisms. A 
minimum of 15 variables was used to ensure that both domains of pain sensitivity and 
psychological distress were included in the model.
 2.4.2. Cluster discovery—In addition to choosing the M variables used to identify the 
clusters, it is also necessary to choose the number of clusters. We denote the number of 
clusters by k. In the second step, sets of M variables were used to identify k clusters within 
each cohort, with k varying from 1 to 8. The gap statistic was used to choose k by evaluating 
the quality of each cluster solution. This second step overcomes another shortcoming of 
conventional cluster analysis, which is that it will produce clusters for any value of k even 
when statistical evaluation fails to reject the null hypothesis that no clusters exist. The gap 
statistic70 can be used as a criterion to address this issue. The gap statistic estimates the 
difference between the within-cluster sum of squares of a putative set of clusters and the 
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expected within-cluster sum of squares under a suitable null distribution with no clusters. 
Because the within-cluster sum of squares should be small for truly “significant” clusters, 
the “best” set of clusters should produce a within-cluster sum of squares that is much smaller 
than expected under the null hypothesis. Thus, one can choose the optimal number of 
clusters by choosing the set of clusters that maximize the gap statistic. If the gap statistic is 
maximized for k = 1 cluster, the implication is that no clusters exist in the data.
Both TMD cases and TMD-free controls were used to identify the clusters. All variables 
were normalized to have mean 0 and SD 1 before applying the clustering method. The 
association between the clusters and chronic TMD and several demographic variables of 
interest was evaluated using chi-square tests. The mean values (and associated SEs) of each 
variable of interest were calculated for each cluster, and the null hypothesis of no difference 
between the cluster means was tested using t-tests and analysis of variance.
To provide further insight into characteristics that distinguished clusters, the association 
between the clusters and several chronic pain conditions known to be comorbid with TMD 
was also evaluated for the OPPERA cohort using chi-square tests. The 4 comorbid 
conditions were irritable bowl syndrome, pelvic pain, chronic headache, and chronic low-
back pain. Irritable bowel syndrome was evaluated based on the Rome III criteria,37 and 
pelvic pain was evaluated using a series of screening questions that have been shown to have 
high sensitivity and specificity for pelvic pain diagnosis.28,46 Chronic headache was defined 
as reporting headaches 15 days or more per month,31 and chronic low-back pain was defined 
as reporting “constant” low-back pain. All 4 conditions were diagnosed based on questions 
from the Comprehensive Pain and Symptom Questionnaire.
 2.4.3. Cluster reliability—The third step was undertaken to verify that the putative 
clusters were reproducible. In both the OPPERA cohort and the UNC cohort, data sets were 
randomly partitioned into a training set and a test set such that the number of TMD cases 
and controls was the same in both partitions. The clustering methodology was applied to the 
training set and the test set of both cohorts. After identifying these putative clusters on both 
halves of the data, a nearest centroid classifier30 was used to predict the test set clusters 
based on the training set clusters. Nearest centroid models calculate the distance between a 
given observation and the centroids of each cluster. The centroid of a cluster is defined to be 
the means of all the observations in that cluster with respect to each variable. Nearest 
centroid classifiers tend to be more accurate than classifications’ methods such as logistic 
regression or linear discriminant analysis when predicting clusters produced by k-means 
clustering. The predictive accuracy of the models was evaluated. The nearest centroid model 
was fit using 4 variables (the trapezius PPT and the somatization, anxiety, and depression 
subscales of the SCL-90R). The rationale for choosing these 4 variables is discussed below.
Two additional nearest centroid classifiers were used to further evaluate the reproducibility 
of the clusters. One classifier predicted the clusters identified in the OPPERA cohort based 
on the clusters identified in the UNC cohort, and the other classifier predicted the UNC 
cohort clusters based on the OPPERA clusters. However, some modifications of the earlier 
procedure were required because of methodological differences in the 2 studies. Because 
different protocols were used when collecting the pain sensitivity and autonomic data in the 
Bair et al. Page 8
Pain. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2 cohorts, one cannot easily fit a model to predict the clusters on one cohort and apply it to 
the other cohort, because the measured variables would be different. Aside from dealing 
with exigencies in these particular data sets, we adopted this strategy in the spirit of a “real-
world” test, in which slightly different protocols are used in different patient care settings, 
yet each protocol is evaluating similar constructs relevant to individuals’ pain. This strategy 
therefore provides insight into the likely utility of using just a handful of measures to 
classify clusters, even when the measures are not identical to the measures used in the 
discovery phase. This procedure also improves generalizability.
Thus, we chose one set of psychological measures (namely, the somatization, anxiety, and 
depression subscales of the SCL-90R) based on their strong association with the clusters in 
both cohorts, because psychosocial summary scores should be comparable across the 2 
cohorts. A single PPT (namely, the trapezius PPT) was also included in the model because 
the distribution of the trapezius PPT measures was comparable in the 2 cohorts, despite the 
fact that different types of algometers were used. The 2 nearest centroid models were fit 
using these 4 variables. Furthermore, when the model that was fit to the OPPERA data was 
applied to the UNC cohort, the data in the UNC cohort were normalized using the mean 
values and SDs calculated in the OPPERA cohort (rather than simply standardized to mean 0 
and SD 1 based on the mean values/SDs in the UNC cohort). This was performed to 
demonstrate that such a model could be used to assign future patients to a cluster, because 
such a classifier would need to be based on the data collected previously. Similarly, the 
model to classify OPPERA cohort participants based on the UNC cohort standardized the 
variables using mean values and SDs calculated based on the UNC cohort.
 2.4.4. Cluster validation—The fourth step evaluated predictive validity66 and was 
based on our premise that, in people without TMD, cluster assignment should be a 
significant predictor of their subsequent risk of developing TMD. The association between 
the putative clusters and first-onset TMD in the OPPERA cohort was evaluated using Cox 
proportional hazards models. Study site was included as a covariate in the model. Only 
initially TMD-free individuals (controls) were included in the analysis. The association 
between the clusters and first-onset TMD was also visualized using a Kaplan–Meier plot. 
Note that this model is intended to predict the likelihood of developing TMD for the groups 
of study participants (ie, participants in a given cluster), not individual participants. The 
nearest centroid model described previously would be used to assign an individual to a 
cluster.
 3. Results
 3.1. Demographic characteristics of study participants
Demographic characteristics of study participants are described in Table 1. The present 
analysis included a total of 1031 chronic TMD cases and 3247 controls from the OPPERA 
cohort and 199 chronic TMD cases and 201 TMD-free controls from the UNC cohort. Note 
that all participants in the UNC cohort are non-Hispanic white females, so no information on 
the sex or race of participants in the UNC cohort is reported in Table 1.
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 3.2. Variable selection and cluster discovery
In the first step of variable screening, the variables most strongly associated with chronic 
TMD were dominated by PPTs and subscales of the SCL-90R, both in the OPPERA and 
UNC cohorts (Supplementary Tables 1 and 2, respectively; available online at http://
links.lww.com/PAIN/A248). When all variables were used in the second step of cluster 
discovery, the gap statistics were maximized for k = 1 cluster, indicating that no clusters are 
present in the data set (Supplementary Figures 1a and 1b, available online at http://
links.lww.com/PAIN/A248). However, when only the top 25 variables were used (or the top 
15 variables for the UNC cohort), the gap statistic was maximized for k = 3 clusters. (Note 
that the values of the gap statistic for different values of M are not comparable. Thus, the 
fact that some values of k produced larger gap statistics when all variables were used does 
not imply that these putative clusters are preferable to the clusters produced for smaller 
values of M. The gap statistic is used only to compare different values of k for a fixed value 
of M). For the results that follow, we therefore applied supervised 3-means clustering to both 
the OPPERA cohort and the UNC cohort based on the M variables that were mostly strongly 
associated with chronic TMD, where M = 25 for the OPPERA cohort and M = 15 for the 
UNC cohort.
The association between the 3 clusters and demographics and chronic TMD in the OPPERA 
cohort is shown in Table 1. We called these 3 clusters the “adaptive cluster,” the “pain-
sensitive cluster,” and the “global symptoms clusters” for reasons that will be described in 
more detail below. The adaptive cluster had the lowest proportion of TMD cases, and the 
global symptoms clusters had the highest proportion of cases. Females and participants aged 
25 and older were more likely to belong to the pain-sensitive and adaptive clusters, although 
no association was observed between the clusters and race. The clusters were also strongly 
associated with TMD case status. Only 8.5% of cases were in the adaptive cluster compared 
with 41.2% of controls, whereas 39.1% of cases were in the global symptoms cluster 
compared with 11.9% of controls.
Figure 1A shows the mean values and associated 95% confidence intervals for a selected 
subset of the pain sensitivity and psychosocial variables in the OPPERA cohort. Each 
variable displayed in the figure was normalized to have mean 0 and SD 1. The mean values 
and associated SEs for all the psychosocial, pain sensitivity, and autonomic variables in each 
cluster in the OPPERA cohort are shown in Supplementary Table 3 (available online at 
http://links.lww.com/PAIN/A248). An interesting pattern emerges when comparing these 
mean values across the 3 clusters. Compared with the adaptive cluster, participants in the 
pain-sensitive cluster are more sensitive to pain-evoking pressure stimuli (ie, PPTs for 
muscle pain sensitivity). Participants in the pain-sensitive cluster also had higher levels of 
various measures of psychological distress compared with the adaptive cluster, although the 
differences were more modest. A different pattern emerged when comparing the pain-
sensitive and global symptoms clusters. Only modest differences were observed between 
these 2 clusters with respect to experimental pain sensitivity, with participants in the pain-
sensitive cluster showing slightly greater sensitivity than those in the global symptoms 
cluster. In contrast, large differences between the pain-sensitive and global symptoms 
clusters were observed with respect to nearly every psychosocial instrument included in the 
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analysis. Thus, individuals in the adaptive cluster have lower pain sensitivity and lower 
psychological distress, individuals in the pain-sensitive cluster have higher pain sensitivity 
but lower psychological distress, and individuals in the global symptoms cluster have higher 
pain sensitivity and higher psychological distress.
Cluster variation in autonomic function in OPPERA is also shown in Supplementary Table 
3. In general, participants in the global symptoms cluster had lower HRV across all 
frequency domain measures than participants in the other 2 clusters. The differences in HRV 
between the adaptive and pain-sensitive clusters were much smaller (and generally not 
statistically significant). Participants in the pain-sensitive cluster generally had lower blood 
pressure than participants in the adaptive cluster. Participants in the global symptoms cluster 
tended to have slightly higher blood pressure than participants in the pain-sensitive cluster, 
although the differences were generally modest. In contrast to measures of blood pressure, 
mean resting heart rates were lowest for participants in the adaptive cluster and highest for 
participants in the global symptoms cluster.
The mean values (and associated SEs) of the clinical variables in each of the 3 clusters for 
TMD cases in the OPPERA cohort are shown in Table 2. Supplementary Table 4 shows 
these results for the full cohort (available online at http://links.lww.com/PAIN/A248). In 
general, participants in the pain-sensitive and global symptoms clusters reported greater 
levels of clinical pain, greater frequency of headaches and other comorbid pain conditions, 
and more bodily pain, including widespread bodily pain, than participants in the adaptive 
cluster, with the global symptoms cluster showing the most severe symptoms. Among TMD 
cases, participants in the global symptoms cluster generally showed more severe and 
anatomically widespread clinical symptoms than participants in the other 2 clusters. 
Participants in the pain-sensitive cluster also reported greater levels of pain, functional 
limitation, and comorbid conditions than those in the adaptive cluster, although the 
differences were smaller than the differences between the global symptoms cluster and the 
other 2 clusters.
Measures of physical functioning and mental health also varied with respect to cluster 
membership. Participants in the adaptive and pain-sensitive clusters reported similar 
physical function, whereas participants in the global symptoms cluster reported much lower 
physical function than those in the other 2 clusters. Mental health function also varied as a 
function of cluster assignment with a clear gradation of highest functioning reported for 
participants in the adaptive cluster and lowest for participants in the global symptoms 
cluster.
The associations between the 3 clusters and chronic TMD and age in the UNC cohort are 
shown in Table 1. Figure 1B shows the mean values and associated 95% confidence intervals 
for a selected subset of the pain sensitivity and psychosocial variables in the UNC cohort. 
(Again, each variable was normalized to have mean 0 and SD 1 in the figure). The mean 
values and associated SEs for all the psychosocial, pain sensitivity, and autonomic variables 
in each cluster in the UNC cohort are shown in Supplementary Table 5 (available online at 
http://links.lww.com/PAIN/A248). The results are consistent with what was observed in the 
OPPERA cohort. The pain-sensitive cluster had a higher proportion of cases than the 
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adaptive cluster, and the global symptoms cluster had a higher proportion of cases than the 
other 2 clusters. In general, participants in the pain-sensitive cluster had higher levels of pain 
sensitivity compared with the adaptive cluster, and participants in the global symptoms 
cluster also had higher levels of pain sensitivity and psychological distress than participants 
in the other 2 clusters. However, the differences in psychological distress between the 
adaptive and pain-sensitive clusters were modest compared with the differences between the 
pain-sensitive and global symptoms clusters. Likewise, the differences in pain sensitivity 
between the adaptive and pain-sensitive clusters were much larger than the differences in 
pain sensitivity between the pain-sensitive and global symptoms clusters, which is consistent 
with what was observed in the OPPERA cohort.
The mean values and associated SEs of the clinical variables in each of the 3 clusters for 
TMD cases in the UNC cohort are shown in Table 3, and Supplementary Table 6 shows 
these results for the full cohort (available online at http://links.lww.com/PAIN/A248). Again, 
the results are consistent with what was observed in the OPPERA cohort. Participants in the 
pain-sensitive and global symptoms clusters reported greater levels of clinical pain, a greater 
number of comorbid pain conditions, and more bodily pain than the participants in the 
adaptive cluster, with the global symptoms cluster showing the most severe symptoms. 
Among TMD cases, participants in the global symptoms cluster reported greater levels of 
pain than participants in the other 2 clusters with respect to every measure of interest. The 
differences between the adaptive and pain-sensitive clusters were not statistically significant 
(with the exception of the number of tender muscle groups/palpation sites during the TMD 
examination). Participants in the global symptoms cluster also reported diminished physical 
function and mental health compared with those in the other 2 clusters.
The association between the clusters and 4 chronic pain conditions known to be comorbid 
with TMD (namely, irritable bowel syndrome, pelvic pain, chronic headache, and chronic 
low-back pain) in the OPPERA cohort is shown in Table 4. Participants in the pain-sensitive 
cluster had higher odds of all 4 conditions than participants in the adaptive cluster, and 
participants in the global symptoms cluster had much higher odds of all 4 conditions than 
participants in the other 2 clusters. The increased odds of these conditions in the pain-
sensitive and global symptoms clusters compared with the adaptive cluster were all strongly 
statistically significant (P < 0.0001).
The association between the clusters and the putative environmental risk factors for TMD is 
shown in Table 5. In both cohorts, participants in the global symptoms cluster were more 
likely to report a lifetime history of smoking or a traumatic life event than participants in the 
other 2 clusters. In the OPPERA cohort, participants in the pain-sensitive and global 
symptoms clusters were more likely to report a lifetime history of jaw injury (with 
participants in the global symptoms cluster most likely to report a history of jaw injury). A 
similar trend was apparent in the UNC cohort, although the differences were not statistically 
significant. Similarly, female participants in the pain-sensitive and global symptoms clusters 
in the OPPERA cohort were more likely to report a lifetime history of hormonal 
contraception use, with participants in the global symptoms cluster most likely to report 
history of hormonal contraception use. However, participants in the global symptoms cluster 
were least likely to report that they are currently using hormonal contraceptives.
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 3.3. Cluster reliability
The cluster reliability results are shown in Table 6. When each cohort was partitioned into a 
training set and a test set, the clusters identified in the training set could be used to predict 
the clusters in the test set with very high accuracy. That is, 96.4% of the observations in the 
OPPERA cohort were classified to the correct cluster, and 83.4% of the observations in the 
UNC cohort were classified correctly. When the clusters in one cohort were used to predict 
the cluster in the other cohort, the predictive accuracy was lower, but still very good. 
Specifically, 80.9% of the observations in the OPPERA cohort were classified to the correct 
cluster based on the UNC cohort data, and 78.3% of the observations in the UNC cohort 
were correctly classified based on the OPPERA cohort data.
 3.4. Cluster validation
The validity of clusters in predicting first-onset TMD was verified with Kaplan–Meier plots 
illustrating a significantly greater hazard of first-onset TMD for subjects in the global 
symptoms cluster compared with either of the other clusters (Figure 2). Participants in the 
global symptoms cluster had significantly higher incidence of first-onset TMD than 
participants in the other 2 clusters (hazard ratio = 2.8, P < 0.0001).
 4. Discussion
Through a novel application of statistical methods, this study identified clusters of 
individuals using a comprehensive array of biopsychosocial risk factors for chronic pain 
measured in each individual.39,62 The numerically smallest global symptoms cluster had a 
profile that, on face value, signified vastly increased risk and severity of pain and also 
physical and mental dysfunction compared with the other 2 clusters. Temporomandibular 
disorder–free participants in the global symptoms cluster had higher risk of first-onset TMD 
compared with the other 2 clusters, consistent with our hypothesis. Meanwhile, among 
participants who had TMD, those in the global symptoms cluster had, by far, the most severe 
symptoms of TMD and the greatest burden of comorbid pain. The supervised clustering 
method proved to be highly reproducible in split-sample reliability assessments, and the 
method was replicated in 2 cohorts. Furthermore, clusters were reliably reproduced using a 
model based on only 4 variables that would be feasible to apply in clinical care. These 
findings provide strong support for the suggestion that TMD is a heterogeneous condition 
consisting of a mosaic of complex biopsychosocial phenotypes. Findings from follow-up of 
initially TMD-free participants also show that it is possible to identify a subgroup of the 
general population that has a higher risk of developing TMD (and possibly other chronic 
pain conditions).
Compared with the adaptive cluster, participants in the pain-sensitive cluster had 
substantially greater sensitivity to experimental pain. They also had slightly greater 
psychological distress, but the differences were modest compared with the differences 
between the global symptoms cluster and the other 2 clusters. Among TMD cases, they had 
greater intensity of TMD pain and more comorbid pain. Although the psychological 
characteristics distinguishing the adaptive and pain-sensitive clusters were strong predictors 
of TMD incidence in the OPPERA study,19 most measures of pain sensitivity were not,25 
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which probably explains why these 2 clusters did not differ in their likelihood of developing 
TMD. However, some pain sensitivity measures increased significantly after TMD 
developed,63 which might explain differences between cases in severity of clinical TMD. 
Taken together, these findings suggest that the adaptive and pain-sensitive clusters differ 
primarily with respect to characteristics that develop as a consequence of TMD or other 
painful conditions, implying that the 2 clusters are more useful in distinguishing between 
individuals with pain than in predicting who will develop pain. Specifically, individuals in 
the adaptive cluster may have more localized pathology, whereas individuals in the pain-
sensitive and global symptoms clusters may have greater general pain sensitivity secondary 
to central sensitization phenomenon. Thus, individuals in the pain-sensitive and global 
symptoms may be more responsive to treatments that target such central mechanisms.
Other studies have used cluster analysis to identify pain-related subtypes among individuals 
with chronic pain or healthy controls.4,10,11,21,23,29,33–35,45,53,60,68,69,72 Among these, the 
Multidimensional Pain Inventory33 (MPI) is probably the best known. The MPI emerged 
from biopsychosocial theory, and studies assessing outcomes based on MPI classification 
indicate that anatomically distinct disorders (headache, TMD, back pain) respond to 
treatments similarly within each cluster.71 The provision of item-response scaling has 
resulted in the recommendation to use dimensional scaling rather than the original 
clusters,57 and problems with temporal stability of the MPI have been identified.5 Finally, 
MPI administration is restricted to individuals who already have pain.
In contrast to these previous cluster efforts, the present approach has several distinguishing 
features. Most previous studies were based on much smaller samples consisting of either 
only individuals with chronic pain or only pain-free controls, whereas our clusters were 
identified using a large cohort (and a smaller secondary cohort for confirmation) that 
consisted of both chronic TMD cases and TMD-free controls. This methodology allowed us 
to identify pain-free individuals who had higher risk of developing chronic pain. This study 
also used a much larger set of biopsychosocial risk factors for pain than previous studies. 
Furthermore, we demonstrated the across-sample reliability and validity of our clusters. This 
is an important step in cluster analysis, because clustering methods will output clusters even 
in homogeneous data sets where no subtypes exist. Most previous clustering studies in the 
area of chronic pain did not demonstrate the reliability of the putative clusters. Finally, we 
showed how one could assign future individuals to clusters using a small set of variables, 
demonstrating that the methodology could be used in a clinical setting.
Other systems have been proposed for classifying individuals with pain that are not based on 
cluster analysis.16,42,73,76 In particular, Mallen et al.42 used a set of 3 questions to accurately 
identify individuals who would develop chronic musculoskeletal pain. Although these 
classification systems are potentially powerful tools, they are somewhat limited by the fact 
that they are only applicable after an individual has developed pain. Our putative clusters 
allow for the identification of a high-risk subpopulation of individuals who are currently 
pain free. Also, our proposed clusters are based on putatively etiological variables rather 
than clinical measures of pain, so they are more likely to represent biologically meaningful 
subtypes rather than simply variations in the severity of pain or consequences of the 
pain.39,62
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A strength of our study is that clusters were reproducible using only 4 variables that are 
feasible to measure in clinical settings. This indicates that it is possible to assign future 
individuals to clusters using a short questionnaire and a few simple algometer 
measurements: cluster membership could be identified quickly and accurately in a clinical 
setting. Our current results provide a “proof of concept” that such a classification method is 
feasible, but it is likely that the classification process can be streamlined by reducing the 
number of items on the questionnaires or selecting different items. Optimizing the model for 
predicting cluster membership to maximize accuracy and minimize patient burden is an area 
for future research.
There are several important implications that stem from this work. First, this method 
represents a new tool by which one can identify subpopulations of individuals with chronic 
pain conditions. Because the method is agnostic to the anatomical location of a persistent 
pain condition, it is likely that the method used in this study will prove useful for stratifying 
individuals with other chronic pain conditions into subtypes or clusters that are based on 
etiological mechanisms rather than anatomically specific signs and symptoms. As such, after 
verifying the reproducibility of these clusters among individuals with other chronic pain 
conditions, we should consider diagnosing individuals with these conditions into these 
clusters. This has the potential to better inform treatment selection and patient management. 
It is possible that the relative efficacy and side-effect profiles of pain treatments will be 
dependent on cluster membership.3
A second implication of this work is its relevance for individuals who have similar 
biopsychosocial characteristics regardless of their anatomically classified chronic pain 
conditions. It is likely that many of these individuals already have higher levels of pain, 
including orofacial pain, compared with the general population. Thus, it is not surprising 
that these individuals are more likely to meet the (anatomically defined) diagnostic criteria 
for TMD in the future. This is likely to be true for other painful conditions and also 
evidenced by the greater number of common persistent pain conditions seen in the global 
symptoms cluster. The identification of individuals at risk for developing more severe 
chronic pain conditions permits the development of proactive pharmacological and 
behavioral approaches that can be used to mitigate this risk.
Several unanswered questions still remain. This study was limited to individuals with TMD 
and TMD-free controls, and we do not know if these clusters apply to other persistent pain 
conditions. Multidimensional Pain Inventory research suggests that generalizability is likely, 
but this needs to be evaluated. We do not know whether one’s cluster assignment is 
temporally stable or whether treatments and future environment events (positive or negative) 
permit an individual to move from one cluster assignment to another. Indeed, only a few 
environmental risk factors were examined in this study, so the association between 
environmental variables and the clusters is still unclear. In addition, we do not know whether 
our approach can be used to predict the severity of acute pain and pain management 
requirements after surgical procedures. Given the impairments seen in pain processing in the 
global symptoms cluster, one would predict that individuals in this cluster should be less 
responsive to treatments, experience more severe acute pain, and be more likely to transition 
into a chronic pain state after injury or a surgical procedure. Future research is needed to 
Bair et al. Page 15
Pain. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
verify this hypothesis and to find effective targeted treatments to prevent this transition to a 
chronic pain state.
In summary, we have used cluster analysis to validly and reliably identify groups of 
individuals based on biopsychosocial risk factors for TMD. Our method shows considerable 
promise as a new approach for classifying individuals with pain into subtypes in a manner 
that is etiologically based and is agnostic to the anatomical location of pain. The findings 
hold promise for individualized diagnosis and treatment of patients with TMD complaints 
and possibly other patients experiencing acute or chronic pain in other regions.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Z-scores of selected variables. These plots show the mean values (and associated 95% 
confidence intervals) for a selected subset of the pain sensitivity and psychosocial variables 
in the (A) OPPERA cohort and (B) UNC cohort. Each variable displayed in the figure was 
normalized to have mean 0 and SD 1. PPT, pressure pain threshold.
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Figure 2. 
Kaplan–Meier plots for first-onset temporomandibular disorder (TMD). This plot shows the 
probability that a participant in a given cluster remains TMD free after a specified number of 
years. HR, hazard ratio.
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Table 1
Demographics, temporomandibular disorder case status, and cluster membership.
OPPERA cohort, n (%) Adaptive cluster (n = 1426) Pain-sensitive cluster (n = 2062)
Global symptoms cluster (n = 
790) P*
Male 839 (58.8) 558 (27.1) 240 (30.4) <0.0001
Female 587 (41.2) 1504 (72.9) 550 (69.6)
Non-Hispanic white 780 (54.7) 1126 (54.6) 455 (57.6) 0.0806
African American 381 (26.7) 596 (28.9) 194 (24.6)
Asian 111 (7.8) 160 (7.8) 69 (8.7)
Hispanic 102 (7.2) 129 (6.3) 42 (5.3)
Other 52 (3.6) 51 (2.5) 30 (3.8)
Age 18–24 730 (51.2) 1027 (49.8) 310 (39.2) <0.0001
Age 25–34 379 (26.6) 593 (28.8) 256 (32.4)
Age 35–44 317 (22.2) 442 (21.4) 224 (28.4)
Cases 88 (6.2) 540 (26.2) 403 (51.0) <0.0001
Controls 1338 (93.8) 1522 (73.8) 387 (49.0)
UNC cohort, n (%) Adaptive cluster (n = 164) Pain-sensitive cluster (n = 154) Global symptoms cluster (n = 
82) P
*
Age 18–24 73 (44.5) 42 (27.3) 19 (23.2) 0.0029
Age 25–34 42 (25.6) 46 (29.9) 26 (31.7)
Age 35–60 49 (29.9) 66 (42.9) 37 (45.1)
Cases 32 (19.5) 99 (64.3) 68 (82.9) <0.0001
Controls 132 (80.5) 55 (35.7) 14 (17.1)
*P value for the null hypothesis that the percentage in each cluster does not differ with respect to the levels of the variable.
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Table 4
Other chronic pain conditions and cluster membership (OPPERA cohort).
Adaptive cluster Pain-sensitive cluster Global symptoms cluster P*
No IBS, n (%) 1387 (34.70) 1944 (48.64) 666 (16.66) <0.0001
IBS, n (%) 21 (9.95) 87 (41.23) 103 (48.82)
No pelvic pain, n (%) 1368 (35.08) 1906 (48.87) 626 (16.05) <0.0001
Pelvic pain, n (%) 23 (11.22) 89 (43.41) 93 (45.37)
No chronic headache, n (%) 1351 (35.00) 1891 (48.99) 618 (16.01) <0.0001
Chronic headache, n (%) 15 (6.25) 86 (35.83) 139 (57.92)
No constant low-back pain, n (%) 1350 (34.26) 1945 (49.37) 645 (16.37) <0.0001
Constant low-back pain, n (%) 44 (17.96) 81 (33.06) 120 (48.98)
*P value for the null hypothesis that the proportion with the condition does not differ between the 3 clusters.
IBS, irritable bowel syndrome.
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